Abstract

Peripheral injection of botulinum neurotoxin A (BoNT/A) has been demonstrated to have a long-term analgesic effect in treating neuropathic pain. Around peripheral nerves, BoNT/A is taken up by primary afferent neurons and inhibits neuropeptide release. Moreover, BoNT/A could also be retrogradely transported to the spinal cord. Recent studies have suggested that BoNT/A could attenuates neuropathic pain by inhibiting the activation of spinal glial cells. However, it remains unclear whether BoNT/A directly interacts with these glial cells or via their interaction with neurons. Our aim here is to determine the direct effect of BoNT/A on primary microglia and astrocytes. We show that BoNT/A pretreatment significantly inhibits lipopolysaccharide (LPS) -induced activation and pro-inflammatory cytokine release in primary microglia (1 U/mL BoNT/A in medium), while it has no effect on the activation of astrocytes (2 U/mL BoNT/A in medium). Moreover, a single intrathecal pre-administration of a low dose of BoNT/A (1 U/kg) significantly prohibited the partial sciatic nerve ligation (PSNL)- induced upregulation of pro-inflammatory cytokines in both the spinal cord dorsal horn and dorsal root ganglions (DRGs), which in turn prevented the PSNL-induced mechanical allodynia and thermal hyperalgesia. In conclusion, our results indicate that BoNT/A pretreatment prevents PSNL-induced neuropathic pain by direct inhibition of spinal microglia activation.

Highlights

  • Neuropathic pain (NP) results from dysfunctions in the sensory nervous system response due to pathology

  • To identify the interaction and function of botulinum neurotoxin A (BoNT/A) on microglia, we examined LPS-activated morphological changes and inflammatory cytokine release in primary microglia with or without BoNT/A pretreatment

  • Without BoNT/A pretreatment, LPS incubation resulted in the gradual transformation of resting microglia into an activated state characterized by an ameboid form, while BoNT/A-pretreated microglia displayed a more ramified cell type (Figure 1B), suggesting that the pretreatment of BoNT/A inhibited the LPS-induced morphological transformation of microglia and, the transition from an inactivated to activated cell type

Read more

Summary

Introduction

Neuropathic pain (NP) results from dysfunctions in the sensory nervous system response due to pathology. The development of NP involves aberrant excitability of the nervous system in primary sensory ganglia (peripheral sensation) and the spinal cord dorsal horn (central sensitization). Spinal microglia and astrocytes play critical roles in central sensitization. Spinal microglia are activated as early as 1 day after peripheral nerve injury and make a critical contribution to the initiation and maintenance of pathological enhanced pain hypersensitivity (Romero-Sandoval et al, 2008; Inoue and Tsuda, 2009). Machanism of BoNT/A in Analgesia symptoms, including spontaneous pain, hyperalgesia and allodynia, which dramatically decreases their quality of life. Available drugs for treatments are limited and there is a lack of effective therapy

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call